Skip to main content

Protagonist Therapeutics, Inc 10-Q for FY2026 Q3

Protagonist Therapeutics, Inc (PTGX)

10-Q 2026-11-06 For: 2026-09-30
View Original
Added on November 06, 2026

About this 10-Q

Protagonist Therapeutics, Inc filed this 10-Q on November 6, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Protagonist Therapeutics, Inc. reported net income of $220,015 thousand for the three months ended September 30, 2026, driven by $274.4 million in collaboration revenue following MIMRYLO approval and Takeda opt-out payments; cash and marketable securities reached approximately $834.6 million. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$274.41M
up 5723.6% from $4.71M a year earlier
Net income
$220.02M
compared with a net loss of $39.34M a year earlier
Diluted EPS
$3.07
compared with -$0.62 a year earlier